Geoff Meacham, an analyst from Citi, maintained the Buy rating on Kymera Therapeutics. The associated price target remains the same with $60.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Geoff Meacham has given his Buy rating due to a combination of factors surrounding Kymera Therapeutics’ promising developments and strong financial position. The company has shown encouraging results with its STAT6 degrader, KT-621, particularly in phase 1 trials with healthy volunteers. This positions the company well for the upcoming phase 1b study in atopic dermatitis, expected to yield significant data in the fourth quarter of 2025. The robust biomarker profile and safety observed so far are promising indicators for future success.
Additionally, Kymera is advancing its IRAK4 and IRF5 programs, with Sanofi taking over the development of KT-485, and KT-579 expected to enter phase 1 testing in early 2026. Financially, Kymera is in a strong position with approximately $1 billion in cash, ensuring a runway until at least 2028. These factors, combined with anticipated catalysts over the next 12-18 months, support the Buy rating, despite the high-risk classification.
According to TipRanks, Meacham is a 3-star analyst with an average return of 1.9% and a 51.15% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Regeneron.
In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $59.00 price target.